A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer Metastatic|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Bladder Cancer|GastroEsophageal Cancer|Renal Cell Carcinoma|MSI-H
Interventions: BIOLOGICAL: EDP1503|BIOLOGICAL: Pembrolizumab
Sponsor: Evelo Biosciences, Inc.
Collaborators: SCRI Development Innovations, LLC|Merck Sharp & Dohme LLC